{
    "clinical_study": {
        "@rank": "137712", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo."
            }, 
            {
                "arm_group_label": "Tacrolimus", 
                "arm_group_type": "Active Comparator", 
                "description": "Tacrolimus 0.1% ointment twice daily for 28 days."
            }, 
            {
                "arm_group_label": "OPA-15406", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the pharmacokinetics and safety of OPA-15406 in\n      adult subjects with atopic dermatitis"
        }, 
        "brief_title": "A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Atopic Dermatitis", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult subjects 18-65 years of age\n\n          -  Diagnosis of atopic dermatitis (AD)\n\n          -  AD affecting at least 5% of total Body Surface Area (BSA) for Part 1 and at least 10%\n             BSA for Part 2, not including face, neck, and head\n\n          -  Have had a positive but inadequate response to one or more treatment course of\n             standard AD therapy including topical steroids, UV light A, narrowband UV B, and UV\n             light B.\n\n        Exclusion Criteria:\n\n        -Use of systemic or topical therapy for contact or atopic dermatitis within 30 days of\n        screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "92", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01702181", 
            "org_study_id": "271-12-204"
        }, 
        "intervention": [
            {
                "arm_group_label": "OPA-15406", 
                "description": "0.3%, 1%, or 3% OPA-15406 topical ointment, applied twice daily for 28 days", 
                "intervention_name": "OPA-15406", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Tacrolimus", 
                "description": "0.1% concentration of tacrolimus.", 
                "intervention_name": "Tacrolimus", 
                "intervention_type": "Drug", 
                "other_name": "Protopic"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tacrolimus"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Atopic Dermatitis, Eczema", 
        "lastchanged_date": "January 16, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Mobile", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "36608"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hot Springs", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "71913"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Irvine", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92697"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orange Park", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32073"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33609"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Carmel", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46032"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08009"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "High Point", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27262"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97210"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "College Station", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77845"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75230"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of subjects with AEs, SAEs, and % of clinically relevant changes from baseline in Draize Scale, physical examinations, vital signs, laboratory assessments, and electrocardiograms.", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "Measurement of drug levels in the blood of treated patients", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01702181"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Investigator's Global Assessment (IGA) of Disease Severity at Week 4", 
            "safety_issue": "No", 
            "time_frame": "28 Days"
        }, 
        "source": "Otsuka Pharmaceutical Development & Commercialization, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Otsuka Pharmaceutical Development & Commercialization, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}